Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Pipeline Review, H1 2017

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0775TDB
  • |
  • Pages: 80
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Pipeline Review, H1 2017

Summary

According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor-Pipeline Review, H1 2017'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.

The report 'Granulocyte Macrophage Colony Stimulating Factor-Pipeline Review, H1 2017' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Respiratory which include indications Rheumatoid Arthritis, Breast Cancer, Melanoma, Solid Tumor, Hepatocellular Carcinoma, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Pancreatic Cancer, Soft Tissue Sarcoma, Bone Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colon Carcinoma, Juvenile Myelomonocytic Leukemia (JMML), Leukemias, Liver Cancer, Lung Adenocarcinoma, Lung Disease, Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Osteoarthritis Pain, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Renal Cell Carcinoma and Squamous Cell Carcinoma.

Scope

The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)

The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)targeted therapeutics and enlists all their major and minor projects

The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Overview

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Companies Involved in Therapeutics Development

Aduro BioTech Inc

Amgen Inc

BriaCell Therapeutics Corp

Cold Genesys Inc

GlaxoSmithKline Plc

Humabs BioMed SA

KaloBios Pharmaceuticals Inc

Morphotek Inc

Sillajen Biotherapeutics

Takeda Pharmaceutical Company Ltd

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Drug Profiles

CG-0070-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG0070 + Immune Checkpoint Modulator-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gimsilumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3196165-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenzilumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

namilumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OrienX-010-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexastimogene devacirepvec-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STINGVAX-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SVBR-1GM-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talimogene laherparepvec-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD40L and GM-CSF for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Dormant Products

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Discontinued Products

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Product Development Milestones

Featured News & Press Releases

May 15, 2017: Cold Genesys Announces Clinical Results at American Urological Association Annual Meeting 2017

May 08, 2017: Scottish Medicines Consortium Rejects Imlygic For Use Within NHS Scotland

May 08, 2017: BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax in Advanced Breast Cancer

Apr 25, 2017: Cold Genesys Announces Acceptance of Late Breaking Abstract at American Urological Association (AUA) Annual Meeting 2017

Apr 24, 2017: SillaJen And Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial For Pexa-Vec in Advanced Liver Cancer

Apr 12, 2017: Transgene and Institut Bergonie Start the Phase 2 Part of the METROmaJX Trial

Mar 15, 2017: BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax in Patients with Advanced Breast Cancer

Mar 07, 2017: BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms

Feb 06, 2017: BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax in Advanced Breast Cancer

Dec 05, 2016: BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory

Nov 29, 2016: Kalobios To Present At JMML International Symposium

Nov 29, 2016: BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax

Nov 10, 2016: BriaCell Provides Clinical Development Update on BriaVax

Oct 26, 2016: BriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director

Oct 06, 2016: Talimogene laherparepvec in melanoma: Added benefit not proven

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Aduro BioTech Inc, H1 2017

Pipeline by Amgen Inc, H1 2017

Pipeline by BriaCell Therapeutics Corp, H1 2017

Pipeline by Cold Genesys Inc, H1 2017

Pipeline by GlaxoSmithKline Plc, H1 2017

Pipeline by Humabs BioMed SA, H1 2017

Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Pipeline by Morphotek Inc, H1 2017

Pipeline by Sillajen Biotherapeutics, H1 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aduro BioTech Inc, Amgen Inc, BriaCell Therapeutics Corp, Cold Genesys Inc, GlaxoSmithKline Plc, Humabs BioMed SA, KaloBios Pharmaceuticals Inc, Morphotek Inc, Sillajen Biotherapeutics, Takeda Pharmaceutical Company Ltd

select a license

Single User License
USD 3500 INR 227290
Site License
USD 7000 INR 454580
Corporate User License
USD 10500 INR 681870

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com